GSK secures exclusive rights to Syndivia’s preclinical ADC for advanced prostate cancer

GSK plc ( NYSE: GSK) and Syndivia on Monday announced an agreement granting GSK exclusive worldwide rights to develop and ...
Fierce Biotech

GSK pens $357M pact with French biotech for preclinical prostate cancer ADC

Fresh from a European cancer conference that was all about antibody-drug conjugates (ADCs), GSK has turned to French biotech ...
pharmaphorum

AZ and Daiichi's TROP2 ADC shows promise in first-line lung cancer

Two years after AstraZeneca splashed out $1 billion upfront for rights to Daiichi Sankyo's TROP2-targeting antibody-drug conjugate DS-1062, the drug has generate promising results in advanced ...